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Summary
INTRODUCTION
 Generally, introduction of new tools is usually done without consultation of the end users. 
There has been need for evidence to support decision making in regard to acceptance and effective 
use of the new diagnostic tools.
 The East Africa Public Health Laboratories Networking Project through Kenya Medical 
Research Institute - Operational Research on Tuberculosis, undertook a study to evaluate new 
diagnostic TB tools which include the Xpert® MTB/RIF (GeneXpert), and the Light Emitting 
Diodes – Florescence Microscopy (LED-FM). These new tools were introduced in five East 
Africa Public Health Laboratories Networking - Operating Research Project satellite sites, by the 
Ministry of Health with support from World Bank since the year 2012. 
OBJECTIVE
 To document user acceptability of new laboratory tuberculosis (TB) diagnostic tools in the 
EAPHLNP OR Project Satellite study sites in Kenya.
METHODOLOGY
 This was a descriptive study using a cross-sectional design. A non-probabilistic convenient 
sampling was used to identify laboratory respondents per site. Sixteen laboratory staff who had 
used the new TB diagnostic tools at the four satellite sites were included in the interviews. A 
questionnaire was used to collect information on user acceptability to utilize the new tuberculosis 
diagnostic tools.  An  in-depth interview guide was included in the discussions with  key informants 
to document the perception of the laboratory staff towards the introduction of new diagnostic 
tools, infrastructure, procurement, turnround time and their future recommendations.
FINDINGS 
 It was noted that user acceptability of new TB diagnostic tools revealed varying levels of 
acceptance for different attributes. All the laboratory staff (100%) indicated that they understood 
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the concept of GeneXpert compared to 75.0 (95%    CI:  53.8 - 96.2) % for LED-FM.  In regard 
to LED, 9/16 (56.3%) respondents rated the tool as poor compared to GeneXpert. 12/16 (75%) of 
the respondents reported that LED-FM had a low turnaround time. 
 A total of 14/16 (87.5%) respondents reported that, there was no clarity on the algorithm 
for use of GeneXpert. Participants reported that, with regard to safety of equipment, GeneXpert 
was better than ZN because, users were not exposed to fumes and was easy to operate. 
 In addition, the staff reported experiencing difficulties in stain preparation for ZN, 
identification and differentiations of bacilli from artifacts.  GeneXpert was reported to detect 
more TB cases than LED and ZN since it was able to amplify low volume / quantities of bacilli.  
CONCLUSION
 GeneXpert was reported to be more preferred diagnostic tool compared to LED-FM. 
However, both tools have challenges when used independently which can be effectively addressed 
through argumentation. Quality of service maybe improved when both tools are used.
[Afr. J. Health Sci. 2019 32(4) : 43 - 48]
Intoduction
 In sub-Saharan Africa sputum smear 
microscopy is the cornerstone for tuberculosis (TB) 
diagnosis especially at peripheral health services.  
 This method is rapid and inexpensive, highly 
specific for Mycobacterium tuberculosis (MTB) in a 
high burden setting [1].  
 Light Emitting Diodes (LEDs) for Florescence 
Microscopy (FM), commonly referred to as Optimized 
Sputum Smear Microscopy (OSSM)  have been 
identified as an alternative to conventional FM for 
screening of  M. tuberculosis [2].
 More recently, technological advancement 
on TB diagnostics has led to the roll out of new and 
rapid diagnostic tests that are potential for the improved 
management and control of TB. 
 These new diagnostic methods are being 
developed for the detection of TB that includes rapid-
culture systems, antigen detection, immune-based 
assays, and nucleic-acid amplification tests. 
 One such tool is the Xpert® MTB/RIF assay 
(GeneXpert), which is a rapid molecular diagnostic and 
automated test that can detect both TB and rifampicin 
resistance, within two hours after starting the test, with 
minimal hands-on technical time. Due to its ability to 
detect MTB better than microscopy, the GeneXpert 
is rapidly being adopted by many countries including 
Kenya.
 
 The World Health Organization (WHO) has 
championed for the need to a strong and comprehensive 
evidence based support decision making with regard to 
the user acceptance of the new and improved diagnostic 
tools and approaches.
 In Kenya and the East Africa region at large, 
to the best of our knowledge there are no studies on the 
user-acceptability that have been carried out before.
 In partnership with international donors, the 
Kenya government through the Ministry of Health 
(MoH) is involved in strengthening the TB control 
strategy by introducing diagnostic tools ranging from 
those operating on simple principles to highly advanced 
automated technologies. [3]
 The East African Public Health Laboratories 
Networking-Operational Research (EAPHLN-OR) 
Project through the Kenya Medical Research Institute 
(KEMRI) have been evaluating new diagnostic 
Tuberculosis (TB) tools. This include, the Xpert® 
MTB/RIF (GeneXpert) and the Lght Emitting Diodes 
(LED) microscopy. 
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 These new tools were introduced in five 
EAPHLNP-OR project satellite study sites by the 
Ministry of Health through the World Bank support 
from the year 2012 at various time period. 
 The laboratory personnel at the sites had an 
opportunity on onsite refresher training on GeneXpert 
and LED-FM competence during the M&E and 
supervision visits by the KEMRI OR Team. 
 The objective of this study was to document 
users (Laboratory Staff) acceptability to utilize new 
TB diagnostic tools introduced in the EAPHLNP OR 
satellite study sites in Kenya.
Methodology
 This was a descriptive study using a cross-
sectional design. A non - probabilistic convenient 
sampling was used to identify laboratory respondents 
per site. 
 All the laboratory staff in the four participating 
satellite sites were targeted for interview. A semi-
structured questionnaire consisting of a close - ended 
(acceptable / not acceptable) questions was used to 
collect information on user acceptability to utilize the 
new diagnostic tools.
 
 In total, 16 laboratory staff filled the 
questionnaire. In addition, purposive sampling was 
used to identify key informant interview respondents. 
Six key informant interviews were conducted by the 
researcher teams.
 On average each interview session consisted 
of 2 participants lasting for about two hours. In total, 8 
participants from the laboratory were interviewed. 
 
 In addition, secondary sources of information 
namely site meetings proceeding which were documented 
during scheduled monitoring and evaluation (M&E) 
visits by EAPHLNP-OR Project Secretariat were also 
used. 
 Content analysis was used to analyze secondary 
information. Additional analysis was carried out using 
grounded theory procedures to allow for generalization 
of emerging themes (referred to as categories), we 
grouped responses according to five categories:  
 
(1)  Laboratory staff perceptions of introducing  
 new diagnostic tools. 
(2)  Infrastructure implications (equipment,   
 laboratory layout & safety installations).
(3) Procurement implications (reagents,   
 consumables, documentations). 
(4)  Implications on sensitivity and turn-a round- 
 time.
(5)  User recommendation of future / new   
 diagnostic tools.
Findings
 User acceptability of new TB diagnostic tools 
revealed varying levels of acceptance for different 
attributes. All the laboratory staff indicated that they 
understood the concept of GeneXpert compared to:
 
 75.0  (95% CI 53.8-96.2)%     for LED-FM. 
A high proportion of respondents (93.7(81.8-100)%) 
reported acceptance to functionality (general layout) of 
GeneXpert compared to; 
  LED-FM (50.0 (25.5-74.5)%). 
 User - friendliness (simplicity of operating) 
GeneXpert was reported by 93.7(81.8-100)% compared 
to;
  69.7(47.2-92.2)% for LED-FM. 
Three-quarter of the participants (75.0(53.8-96.2)%) 
indicated acceptance to GeneXpert on turn-a-round 
time of results for diagnosing TB, compared to;
 37.5(13.8-61.2)%. 
 Similarly, three-quarter of the participants 
(75.0(53.8-96.2)%) indicated acceptance to GeneXpert 
on turnaround time on results for diagnosing MDR-TB. 
 Close to one-third of the participants 
(37.5(13.8-61.2)% indicated acceptance GeneXpert 
on rating of management of specimen workload and 
using the new platform, compared to; 
 50.0(25.5-74.5)% on LED-FM. 
Over 50% of the participants
 (56.2%; 95% CI = 31.9% - 80.5%) indicated 
acceptance to GeneXpert on overall rating compared 
to other tools,  compared to 43.7(19.4%-68.0%) rating 
on LED-FM.(see Table 1).






% (95% CI) % (95% CI)
Understanding of the concept of 
the new diagnostic platform 
(yes / no)
100 (N/A) 75.0 (53.8-96.2)
Functionality (general layout) 
(acceptable / not-acceptable) 93.7 (81.8-100) 50.0 (25.5-74.5)
User-friendliness (simplicity) of 
using the new tool 
(acceptable / not-acceptable)
93.7 (81.8-100) 69.7 (47.2-92.2)
Turnaround time of
results for diagnosing TB 
(acceptable / not-acceptable)
75.0 (53.8-96.2) 37.5 (13.8-61.2)




Rating of management of specimen 
workload and using the new 
platform
(acceptable / not-acceptable)
37.5 (13.8-61.2) 50.0 (25.5-74.5)
Rating of new tool compared 
to other tools (acceptable / not-
acceptable)
56.2 (31.9-80.5) 43.7 (19.4-68.0)
 A total of 14(87.5% 95%CI=71.3%-100%) of the 
respondents reported that they were not conversant with 
the use of  National TB Diagnostic Case Algorithm.
Qualitative Findings
 From the in-depth interviews, the staff 
reported experiencing difficulties in stain preparation, 
identification and differentiations of bacilli from 
artifacts while using conventional methods of TB 
diagnostic.
“The GeneXpert has made our work easy. 
All TB samples are analyzed using
 this machine…” 
Participant #1, Kitale.
 “…sometimes some people can get 
confused when identifying 
artifacts and bacilli. 
They look the same and one 
needs time which we do not have
 since we have a lot of work…..
” Participant #2, Kitale.
Table 1: Comparison Of GeneXpert and Led Microscopy Tools Evaluation For User Acceptability Parameters
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 GeneXpert was reported to be better than ZN 
because users were not exposed to fumes and easy to 
operate. Thus it was safe to use and does not required 
expansive physical to setup. 
“I like GeneXpert, 
it has made my work simple.
 The bench is clean, 
one does not have to 
do staining and mounting of 
slides under the hood…..” 
Participant #1, Malindi.
 In some sites, they reported they had no storage 
space in the laboratory for storing the GeneXpert 
cartridge which required large cabinets. Some Sites 
experienced irregular supply of reagents for both 
GeneXpert and LED-FM.
“… last week, PCU brought us 
a lot of cartridges from Nairobi. 
That is why you see these supplies still 
on table and on that shelve……..
” Participant #1, Kitale.
 Out of the 16 respondents, 12 of them reported 
that LED-FM had a low turn-around time. GeneXpert 
detected more TB cases than LED and ZN since it was 
able to amplify low volume / quantities of bacilli. 
 
“Most of us see LED-FM as a 
user-friendly tool, 
but has chances of errors
 associated with 
user capacity 
may lead to its unreliability. 
However, in a high workload facility like ours,
 we prefer to use GeneXpert 
since it can amplify low volume of TB bacilli.” 
Participant #2, Malindi.
 GeneXpert tool was used as the first diagnostic 
test for all tuberculosis suspects. Respondents viewed 
the continuation of GeneXpert as a first line of TB 
diagnosis as very likely and very positive about it.
“We were informed by the National Programme
 that all patients in chest clinics, 
should have their sputum tests done 
using GeneXpert as 
a first line of diagnostic test.
” Participant # 1, Busia
Discussion
 This study has elicited new user perception on 
new TB diagnostic tools in field-setting. GeneXpert tool 
was the preferred TB diagnostic tool compared to LED-
FM microscopy on different attributes. The rationale 
and adaption of the new tools in laboratories was said to 
be due to ease of operation and high turnaround time. 
 These attributes may have contributed to 
GeneXpert becoming more acceptable compared to 
other technologies. 
 In addition, revised national TB diagnostic 
guidelines indicate that, GeneXpert was to be the first 
line tool for TB diagnostic. 
 Barriers towards using GeneXpert include 
equipment breakdown, calibration schedule not being 
followed, occasional stock-outs of reagents and low 
throughput that may have resulted to high workload. 
 However, due to high workload LED-FM was 
preferred over GeneXpert. In both cases, these new tools 
were preferred over other tools not included in this study 
such as ZN which was used as the benchmark for the 
validation of the new diagnostic tool in the TB study at 
the study site (Githui, 2014). Majority of the respondents 
reported they understood the working principles of the 
GeneXpert. 
 This represents a positive experience in terms 
of operational knowledge of new technologies. Which 
noting that, adaption of new tools and procedures were 
partially associated with the presence of well-qualified 
and experienced personnel in laboratories at any one 
time [4]. 
 
 Challenges associated with use of LED-FM 
include low turnaround time. This study did not probe 
for specific reasons why the low turnaround time. 
LED-FM was rated poor by 9/16 (56.2%) respondents 
compared to newer diagnostic tools. 
 They reported experiencing difficulties in 
identification of bacilli as well as differentiating bacilli 
from artifacts and preparation of stains. In addition, 
they reported that, LED-FM was not user - friendly and 
they felt uncomfortable with the general layout of that 
equipment. 
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 These challenges could be overcome by 
laboratories augmenting multiple diagnostic methods 
at their use and would obtain near accuracy and 
comparable results to improve quality of service [5] 
Conclusion
 GeneXpert was reported to be more preferred 
diagnostic tool compared to LED-FM. 
 However, both tools have challenges when 
used independently which can be effectively addressed 
through argumentation. 
Implications for Practice
Quality of service maybe improved when both tools are 
used.
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